SERDs in Focus: Optimizing Treatment Strategies in HR+ HER2- Breast Cancer - Episode 2
Endocrine Sensitivity and the Prognostic and Clinical Implications
Dr. Gandhi and Dr. Clifton explore the prevalence and mechanisms of resistance to first-line endocrine therapy combined with CDK4/6 inhibitors in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.
Video Player is loading.
Video content above is prompted by the following:
- What proportion of patients with HR+/HER2– breast cancer experience resistance to first-line endocrine therapy plus CDK4/6 inhibitor?
- What are some of the mechanisms of resistance that can emerge following endocrine therapy and CDK4/6 inhibitors in HR+/HER2– breast cancer?
- How you think about endocrine resistance in the post-CDK4/6 setting? What signals—clinical, molecular, or otherwise—influence your treatment sequencing decisions?
- How does treatment resistance after first-line treatment create challenges in selecting second-line therapies?
Related Content:
